Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: Results of a 12-month phase III clinical trial

UroToday International Journal

Volumn 4, Issue 6, 2011, Pages

  Gittelman, Marc ^a   Brown, T Michelle ^b   Holm Larsen, Tove ^c   Persson, Bo Eric ^d  

^a South Florida Medical Research   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c The Right Value Story   (Denmark)

^d Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Degarelix; Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; Health related quality of life; Leuprolide; Prostate

Indexed keywords

EID: 84055176363     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Roth AJ, Weinberger MI, Nelson CJ, et al. Prostate cancer: psychosocial implications and management. Future Oncol. 2008;4(4):561-568.
2. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol. 2010;183:2206-2212.
3. Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol. 2003;169:1653-1661
4. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178:2260-2267.
5. Gomella LG, Johannes J, Trabulsi EJ. Current prostate cancer treatments: effect on quality of life. Urology. 2009;73(suppl 5):S28-35.
6. Litwin MS, Shpall AI, Dorey F, et al. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol. 1998;21:327-332.
7. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998;90(20):1537-1544
8. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology. 2002;11:401-414.
9. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormonereceptor antagonists. Lancet. 2001;358(9295):1793-1803.
10. Wilson S. Downsizing and prostate cancer. Rev Urol. 2004;6(suppl 7):S19-24.
11. Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3:127-140
12. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531-1538.
13. Ware JE Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
14. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1171-1178.
15. SF questionnaires: The SF-12, 2009. http://www.sf-36.org/ tools/sf12.shtml. Accessed November 1, 2011
16. EORTC Group for Research into Quality of Life: EORTC QLQ-C30. http://groups.eortc.be/qol/questionnaires_ qlqc30.htm. Accessed November 1, 2011
17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
18. Cohen J. Statistical power analysis for the behavioral sciences. London. Academic Press; 1969
19. Van Poppel H. LHRH agonists versus GnRH antagonists for the treatment of prostate cancer. Belgian Journal of Medical Oncology. 2010;4:18-22.
20. Schenker N, Gentleman JF. On judging the significance of differences by examining overlap between confidence intervals. The American Statistician. 2001;55:182-186